Reveals that researchers who are developing lentivirus-based gene therapies fear that U.S. Food and Drug Administration policy decisions will depend more on emotional responses from the public rather than on assessments of safety data. Safety features incorporated into lentivirus vectors; Plans of the agency to closely monitor testing of the gene therapy.